Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
A beautiful autumn for Covid-19 test makers
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
A lull in FDA Covid-19 test authorisations
Just as demand for coronavirus tests is peaking, the US regulator has a quiet week.
Qiagen enters the T-cell testing fray
At least two groups have posted early data on T-cell tests for Covid-19; now Qiagen has licensed tech to make its own.
US cuts fees for Covid-19 tests
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
Orthopaedics companies’ nightmare quarter
The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
